Phase 2 data for ERLEADA® ▼(apalutamide) plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localised prostate cancer shows 100 percent biochemical free recurrence rate more than two years post-surgery
May 03, 2024 12:39 ET
|
Janssen Cilag International NV
Study highlights opportunity for treatment intensification in this population since approximately 50 percent of patients with high-risk localised prostate cancer (HRLPC) experience disease recurrence...
TAR-200 monotherapy shows greater than 80 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer
May 03, 2024 11:53 ET
|
Janssen Cilag International NV
New data from Phase 2b SunRISe-1 study show rapid achievement of complete response (CR) with 98 percent achieving a CR within 12 weeks1 TAR-200 provides durable CRs in patients with Bacillus...
Johnson & Johnson submits regulatory applications to European Medicines Agency for TREMFYA® (guselkumab) for treatment of patients with ulcerative colitis and Crohn’s disease
May 01, 2024 06:55 ET
|
Janssen Cilag International NV
Media contact:Sophie DaneauSdaneau@its.jnj.com+33 6 3178 8798Investor contact:Raychel Kruperinvestor-relations@its.jnj.com For European and UK medical and trade media only For immediate...
Janssen to adopt Johnson & Johnson brand as the Company celebrates 100 years of operating in the UK
May 01, 2024 03:00 ET
|
Janssen Cilag International NV
Johnson & Johnson marks new era in the UK with updated visual identity High Wycombe, UK, May 01, 2024 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced it is updating its brand and...
Johnson & Johnson recibe la opinión positiva del CHMP para RYBREVANT®▼ (amivantamab) en combinación con quimioterapia para el tratamiento de primera línea de pacientes con cáncer de pulmón no microcítico (CPNM) avanzado con mutaciones activadoras de inserción en el exón 20 del receptor del EGFR
April 30, 2024 12:28 ET
|
Janssen Cilag International NV
Esta opinión positiva del CHMP sitúa a amivantamab como una nueva opción de tratamiento y como el primer anticuerpo biespecífico totalmente humano dirigido contra los receptores del factor de...
Johnson & Johnson riceve il parere positivo del CHMP per RYBREVANT®▼ (amivantamab) in combinazione con la chemioterapia per il trattamento di prima linea di pazienti con carcinoma polmonare non a piccole cellule in stadio avanzato con mutazioni attivanti da inserzione nell’esone 20 dell’EGFR
April 30, 2024 12:20 ET
|
Janssen Cilag International NV
Il parere positivo del CHMP stabilisce che amivantamab rappresenta una nuova opzione, nonché il primo anticorpo bispecifico EGFR-MET completamente umano, nel trattamento di prima linea del NSCLC con...
Johnson & Johnson receives positive CHMP opinion for RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations
April 26, 2024 07:55 ET
|
Janssen Cilag International NV
This positive CHMP opinion establishes amivantamab as a new option, and the first fully-human EGFR-MET bispecific antibody, in the first-line treatment of EGFR exon 20 insertion-mutated NSCLC ...
CARVYKTI®▼ (Ciltacabtagen Autoleucel; Cilta-cel) ist die erste von der Europäischen Kommission zugelassene BCMA-gerichtete Therapie für die Behandlung von Patienten mit rezidiviertem und refraktärem Multiplem Myelom, die mindestens eine vorherige Therapielinie erhalten haben
April 24, 2024 11:58 ET
|
Janssen Cilag International NV
Die erweiterte Indikation für diese einmalig verabreichte Infusion kann Patienten mit Multiplem Myelom bereits nach dem ersten Rückfall eine behandlungsfreie Zeit ermöglichen1 Die Zulassung wurde...
CARVYKTI®▼ (ciltacabtagén autoleucel; cilta-cel) es el primer tratamiento dirigido a BCMA aprobado por la Comisión Europea para pacientes con mieloma múltiple en recaída y refractario que hayan recibido al menos una línea previa de tratamiento
April 24, 2024 11:57 ET
|
Janssen Cilag International NV
La indicación ampliada de esta dosis única para perfusión puede ofrecer a los pacientes de mieloma múltiple un periodo libre de tratamiento desde la primera recaída1 La aprobación se basa en los...
CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy
April 22, 2024 06:41 ET
|
Janssen Cilag International NV
Expanded indication for this one-time infusion may provide patients with a potential period away from their multiple myeloma treatment as early as first relapse1 Approval is based on results...